Table 1 Demographic and clinical features of the participants
Diagnosis | Development Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|---|
Not or non-reactive NS | Reactive NS | P value | Not or non-reactive NS | Reactive NS | P value | |
N | 44 | 104 | 40 | 27 | ||
Sex, n (%) | 0·219 | 0·432 | ||||
Male | 33 (75·0) | 87 (83·7) | 26 (65·0) | 20 (74·1) | ||
Female | 11 (25·0) | 17 (16·3) | 14 (35·0) | 7 (25·9) | ||
Age, years, mean (SD) | 46·4 (13·7) | 47·3 (11·8) | 0·694 | 48·75 (13·40) | 52·96 (16·32) | 0·252 |
≥45 | 22 (50·0) | 62 (59·6) | 0·19 | |||
< 45 | 22 (50·0) | 42 (40·4) | ||||
Height, cm, mean (SD) | 164·3 (7·8) | 166·5 (7·7) | 0·208 | 165·50 (8·46) | 166·63 (7·98) | 0·585 |
Weight, kg, mean (SD) | 61·4 (9·6) | 62·9 (11·4) | 0·542 | 71·13 (20·89) | 68·92 (12·59) | 0·642 |
Education level, n (%) | 0·110 | 0·197 | ||||
High school or beyond | 19 (44·2) | 30 (30·3) | 13 (32·5) | 13 (48·1) | ||
Beyond high school | 24 (55·8) | 69 (69·7) | 27 (67·5) | 14 (51·9) | ||
Address, n (%) | 0·088 | 0·202 | ||||
City | 24 (55·8) | 33 (33·0) | 9 (22·5) | 5 (18·5) | ||
Urban-rural fringe area | 5 (11·6) | 14 (14·0) | 6 (15·0) | 5 (18·5) | ||
Village and town | 14 (32·6) | 47 (47·0) | 18 (45·0) | 17 (63·0) | ||
Other province of China | 0 (0·0) | 4 (4·0) | 6 (15·0) | 0 (0·0) | ||
Aboard | 0 (0·0) | 2 (2·0) | 1 (2·5) | 0 (0·0) | ||
Treatment before, n (%) | 15 (43·9) | 28 (27·7) | 0·207 | 22 (55·0) | 12 (44·4) | 0·347 |
Clinical symptoms, n (%) | ||||||
No symptom | 6 (13·6) | 8 (7·7) | 0·259 | 5 (12·5) | 3 (11·1) | 0·863 |
Psychiatric behaviour disorders | 9 (20·5) | 52 (50·0) | < 0·001 | 8 (20·0) | 7 (25·9) | 0·568 |
Memory change | 9 (20·5) | 40 (38·5) | 0·033 | 7 (17·5) | 5 (18·5) | 0·915 |
Sleep difficulty | 5 (11·4) | 23 (22·1) | 0·127 | 1 (2·5) | 1 (3·7) | 0·776 |
Photophobia | 6 (13·6) | 8 (7·7) | 0·259 | 2 (5·0) | 1 (3·7) | 0·801 |
Blurred Version | 4 (9·1) | 6 (5·8) | 0·462 | 3 (7·5) | 1 (3·7) | 0·520 |
TP CLIA, mean (SD) | – | – | – | 57·3 (42·0) | 93·3 (49·9) | 0·002 |
1 < X < 100, n (%) | 7 (16·3) | 1 (1·0) | 24 (60·0) | 7 (25·9) | ||
X > 100, n (%) | 36 (83·7) | 99 (99·0) | 16 (40·0) | 20 (74·1) | ||
Creatine kinase, mean (SD), U/L | 106·5 (137·3) | 196·5 (373·0) | 0·132 | – | 63·3 (15·1) | – |
Elevated CK, n (%) | 2 (4·8) | 20 (20·6) | 0·019 | – | 0 (0) | – |
Serum TRUST, n (%) | < 0·001 | 0·008 | ||||
Negative | 9 (22·5) | 3 (3·0) | 15 (37·5) | 1 (4·0) | ||
1 | 14 (35·0) | 9 (9·0) | 19 (47·5) | 11 (44·0) | ||
8 | 5 (12·5) | 7 (7·0) | 4 (10·0) | 5 (20·0) | ||
16 | 6 (15·0) | 18 (18·0) | 1 (2·5) | 3 (12·0) | ||
32 | 4 (10·0) | 30 (30·0) | 0 (0·0) | 1 (4·0) | ||
≥ 64 | 2 (5·0) | 33(33·0) | 1 (2·5) | 4 (16·0) | ||
Serum TPPA > 1:320, n (%) | 36 (81·8) | 96 (92·3) | 0·060 | 35 (87·5) | 25 (96·2) | 0·130 |